Asset
Pociredir
Fulcrum Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04586985 | phase1 | completed | 2020-10-26 | 2022-11-15 | Fulcrum Therapeutics | Safety, Tolerability and Pharmacokinetics of FTX-6058 |
FDA applications (0)
This company has no applications containing this asset.